loading

Perché le azioni Sarepta Therapeutics Inc (SRPT) sono in ribasso?

Abbiamo notato un calo di 42.12% nelle azioni di Sarepta Therapeutics Inc (SRPT) durante la sessione di negoziazione di 2025-06-16. Sebbene ciò possa essere attribuito alla normale volatilità o a vari fattori interni ed esterni, tieni presente che stiamo monitorando attivamente la situazione e forniremo aggiornamenti tempestivi il prima possibile!
2023-06-23:

SRPT's stock fell 7.93% as some analysts voiced concerns that upcoming confirmatory trial data for its gene therapy to treat Duchenne muscular dystrophy (DMD) may not be enough to secure approval for expanded use.

https://www.reuters.com/business/healthcare-pharmaceuticals/sarepta-slumps-concerns-emerge-around-upcoming-gene-therapy-data-2023-06-23/

2023-04-13:

Before the market opened on Thursday, shares of Sarepta Therapeutics (NASDAQ: SRPT) experienced a decline of roughly 10% in pre-market trading. This drop occurred following a report stating that the U.S. Food and Drug Administration (FDA) staff had a leaning towards rejecting the company's Duchenne muscular dystrophy gene therapy, but a senior official intervened.

https://www.investing.com/news/stock-market-news/sarepta-tumbles-10-on-report-fda-leaned-toward-rejecting-duchenne-therapy-432SI-3054655

2023-03-17:

Sarepta Therapeutics's stock is going down today after the announcement of an advisory meeting for the SRP-9001's development (the first gene therapy) with the FDA, since their gene therapy isn't believed to be beneficial. The meeting comes as the company was preparing for the SRP-9001 regulatory action date on May 29, 2023.

$20.39
price down icon 1.66%
$35.96
price up icon 0.17%
$22.56
price up icon 6.51%
$97.32
price down icon 0.14%
$107.09
price down icon 0.39%
biotechnology ONC
$242.48
price down icon 0.70%
Capitalizzazione:     |  Volume (24 ore):